Blog | HemaCare

Novel iPSC Platform to Study Host-Pathogen Interaction

Apr 29, 2015 1:00:10 PM / by Shweta posted in drug screening, cellular reprogramming, disease-state cells, Drug Discovery, iPSCs, Stem Cells, Infectious Disease

0 Comments

iPSC technology helps scientists model liver-stage malaria in a dish

Malaria is a parasitic disease which kills millions of lives worldwide. The life cycle of the parasite revolves between a mosquito vector and a human host. Malaria is transmitted when Anopheles mosquitoes bite a human being and release hundreds of sporozoites into the bloodstream of the host. After entering into the bloodstream, parasites migrate to the liver, where they can either remain dormant or initiate an asexual multiplication cycle to produce thousands of merozoites. The newly formed merozoites attack red blood cells and further initiate the asexual replication cycle. Some of the merozoites differentiate into male and female gametocytes, which are the only parasite form that can be transmitted from humans to the mosquito vector.

Read More

A Small Step Forward for Cancer Immunotherapy Utilizing NK Cells

Mar 25, 2015 1:00:44 PM / by Daisy Goodrich posted in Cancer, Drug Discovery, NK Cells, Immunotherapy (Immunology)

0 Comments

Investigators are experimenting with how to deliver a new drug, interleukin-15, which enhances the beneficial effects of NK cells for cancer patients

Read More

Cancer Drug Targeting T cells: The CTLA-4 Checkpoint Inhibitor

Mar 23, 2015 1:00:53 PM / by Daisy Goodrich posted in Cancer, Dendritic Cells, Drug Discovery, T Cells

0 Comments

Immune checkpoints modulate either the activation or downplay of T cells but can be manipulated by cancer cells. We can strike back with newer drugs.

Read More

What Can Stem Cell Therapy Learn from Pharma Development? 

Jan 21, 2015 1:00:24 PM / by Maria posted in Assay Development, Drug Discovery, Stem Cell Therapy, Basic Research, Immunotherapy (Immunology)

0 Comments

What lessons can stem cell therapy take from pharmaceutical development?
Image credit: Public health image library 18143
Read More

Novel Therapeutic Target to Treat Drug Resistant Chronic Myeloid Leukemia

Jan 12, 2015 1:00:53 PM / by Shweta posted in Cancer, Drug Discovery

0 Comments

Scientists have identified an alternative to reduce the risk of drug resistance in chronic myeloid leukemia patients

Chronic Myeloid Leukemia (CML) is characterized by an uncontrolled proliferation of white blood cells and their precursors. Chronic Myeloid Leukemia develops because of a balanced genetic translocation, which involves a fusion of the Abelson oncogene (ABL) from chromosome 9q34 with the breakpoint cluster region (BCR) gene on chromosome 22q11.2. This reshuffling is called the Philadelphia chromosome. The BCR-ABL fusion oncogene, which is a consequence of this molecular translocation, translates a protein known as Bcr-Abl oncoprotein. This protein, also known as a tyrosine kinase, leads to an uncontrolled proliferation of white blood cells and their precursors.

Read More

      Subscribe Here!

      Posts by Topic

      see all

      Recent Posts